Treatment options for the management of hypertriglyceridemia: Strategies based on the best-available evidence

Journal of Clinical Lipidology

Volumn 6, Issue 5, 2012, Pages 413-426

  Maki, Kevin C ^a   Bays, Harold E ^b   Dicklin, Mary R ^a  

^a Biofortis Clinical Research   (United States)

^b LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

Author keywords

Coronary heart disease; Fibrates; Hypertriglyceridemia; Low density lipoprotein cholesterol; Niacin; Omega 3 fatty acids; Statins; Triglycerides

Indexed keywords

ATORVASTATIN; ATYPICAL ANTIPSYCHOTIC AGENT; BEZAFIBRATE; CYCLOSPORIN; DIURETIC AGENT; DOCOSAHEXAENOIC ACID; ESTROGEN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; ISOTRETINOIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PITAVASTATIN; PLACEBO; PRAVASTATIN; PROPRANOLOL; PROTEINASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN; TACROLIMUS; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ALCOHOL CONSUMPTION; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBRAL REVASCULARIZATION; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FOLLOW UP; FOOD INTAKE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LONG TERM CARE; LOW FAT DIET; MORBIDITY; PANCREATITIS; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SMOKING CESSATION; TREATMENT OUTCOME; WEIGHT REDUCTION;

EVIDENCE-BASED MEDICINE; HUMANS; HYPERTRIGLYCERIDEMIA; LIFE STYLE; LIPID METABOLISM; RISK;

EID: 84866732882     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2012.04.003     Document Type: Review

References (145)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
2. K.M. Flegal, M.D. Carroll, C.L. Ogden, and C.L. Johnson Prevalence and trends in obesity among US adults, 1999-2000 JAMA 288 2002 1723 1727
3. E.S. Ford, C. Li, G. Zhao, W.S. Pearson, and A.H. Mokdad Hypertriglyceridemia and its pharmacologic treatment among US adults Arch Intern Med 169 2009 572 578
4. M. Miller, N.J. Stone, C. Ballantyne American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association Circulation 123 2011 2292 2333
5. U.S. Census Bureau. The 2011 Statistical Abstract. Available at: http://www.census.gov/compendia/statab/. Accessed April 23, 2012.
6. G. Assmann, H. Schulte, and A. von Eckardstein Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged men Am J Cardiol 77 1996 1179 1184
7. J.E. Hokanson, and M.A. Austin Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies J Cardiovasc Risk 3 1996 213 219
8. N. Sarwar, J. Danesh, and G. Eiriksdottir Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 prospective studies Circulation 115 2007 450 458
9. J. Labreuche, P.J. Touboul, and P. Amarenco Plasma triglyceride levels and risk of stroke and carotid atherosclerosis: a systematic review of the epidemiological studies Atherosclerosis 203 2009 331 345
10. H.N. Ginsberg New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism Circulation 106 2002 2137 2142
11. I.J. Goldberg, R.H. Eckel, and R. McPherson Triglycerides and heart disease: Still a hypothesis? Arterioscler Thromb Vasc Biol 31 2011 1716 1725
12. W.C. Cromwell, and T.A. Barringer Low-density lipoprotein and apolipoprotein B: clinical use in patients with coronary heart disease Curr Cardiol Rep 11 2009 468 475
13. J.D. Otvos, S. Mora, I. Shalaurova, P. Greenland, R.H. Mackey, and D.C. Goff Jr. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number J Clin Lipidol 5 2011 105 113
14. M. Rizzo, and K. Berneis Low-density lipoprotein size and cardiovascular risk assessment Q J Med 99 2006 1 14
15. H. Bays, S. Conard, and L.A. Leiter Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading? Lipids Health Dis 30 2010 136
16. A.T. Lada, and L.L. Rudel Associations of low density lipoprotein particle composition with atherogenicity Curr Opin Lipidol 15 2004 19 24
17. M.A. Austin, M.C. King, and K.M. Vranzan Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk Circulation 82 1990 495 506
18. 2 mass in statin-treated subjects with hypertriglyceridemia J Clin Lipidol 3 2009 332 340
19. M.H. Davidson, H.E. Bays, E. Stein TRIMS Investigators Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects Clin Cardiol 29 2006 268 273
20. G.M. Reaven, Y.D. Chen, and J. Jeppesen Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles J Clin Invest 92 1993 141 146
21. K.C. Maki Fibrates for the treatment of the metabolic syndrome Curr Atheroscler Rep 6 2004 45 51
22. K.C. Maki, R. Galant, and M.H. Davidson Non-high density lipoprotein cholesterol: the forgotten therapeutic target Am J Cardiol 96 Suppl 2005 59K 64K
23. M.H. Davidson Strategies to improve Adult Treatment Panel III guideline adherence and patient compliance Am J Cardiol 89 Suppl 2002 8C 22C
24. S.M. Grundy, J.I. Cleeman, C.N. Merz National Heart, Lung, and Blood Institute; American College of Cardiology; American Heart Association Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
25. A. Sniderman, M. McQueen, and J. Contois Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol J Clin Lipidol 4 2010 152 155
26. J. Elovson, J.E. Chatterton, and G.T. Bell Plasma very-low-density lipoproteins contain a single molecule of apolipoprotein B J Lipid Res 29 1988 1461 1473
27. J. Liu, C.T. Sempos, and R.P. Donahue Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease Am J Cardiol 98 2006 1363 1368
28. M.H. Davidson Apolipoprotein measurements: is more widespread use clinically indicated? Clin Cardiol 32 2009 482 486
29. M.H. Davidson, C.M. Ballantyne, and T.A. Jacobson Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists J Clin Lipidol 5 2011 338 367
30. H.E. Bays Rationale for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia: a primer for clinicians Drugs Today 44 2008 205 246
31. A.J. Nordmann, A. Nordmann, and M. Briel Effects of low-carbohydrate vs. low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials Arch Intern Med 166 2006 285 293
32. C.D. Gardner, A. Kiazand, and S. Alhassan Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial JAMA 297 2007 969 977
33. E.J. Parks Effect of dietary carbohydrate on triglyceride metabolism in humans J Nutr 131 2001 2772S 2774S
34. S.K. Fried, and S.P. Rao Sugars, hypertriglyceridemia, and cardiovascular disease Am J Clin Nutr 78 Suppl 2003 873S 880S
35. K.L. Stanope, and P. Havel Fructose consumption: recent results and their potential implications Ann N Y Acad Sci 1190 2010 15 24
36. E. Theuwissen, J. Plat, and C.J. van der Kallen Plant stanol supplementation decreases serum triacylglycerols in subjects with overt hypertriglyceridemia Lipids 44 2009 1131 1140
37. I. Demonty, R.T. Ras, and H.C.M. van der Knaap Continuous dose-response relationship of the LDL-cholesterol-lowering effect of phytosterol intake J Nutr 139 2009 271 284
38. I. Eleftheriadou, P. Grigoropoulou, and N. Katsilambros The effects of medications used for the management of diabetes and obesity on postprandial lipid metabolism Curr Diabetes Rev 4 2008 340 356
39. J.R. Crouse 3rd Hypertriglyceridemia: a contraindication to the use of bile acid binding resins Am J Med 83 1987 243 248
40. ® (atorvastatin calcium) Tablets. Prescribing information June 2009 Parke-Davis, Division of Pfizer Inc. New York
41. ® (rosuvastatin calcium) Tablets. Prescribing information May 2011 AstraZeneca Pharmaceuticals LP Wilmington, DE
42. ® (simvastatin) Tablets. Prescribing information June 2011 Merck & Co., Inc. Whitehouse Station, NJ
43. LESCOL® XL (fluvastatin sodium 80 mg). Prescribing information July 2011 Novartis Pharmaceuticals Corporation East Hanover, NJ
44. P.H. Jones, M.H. Davidson, E.A. Stein for the STELLAR Study Group Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR) trial Am J Cardiol 92 2003 152 160
45. J.M. McKenney, P.H. Jones, A. Adamczyk for the STELLAR Study Group Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial Curr Med Res Opin 19 2003 689 698
46. J.M. McKenney Efficacy and safety of rosuvastatin in treatment of dyslipidemia Am J Health Syst Pharm 62 2005 1033 1047
47. J. Sasaki Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia Vasc Health Risk Manag 6 2010 997 1005
48. H. Bays Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids Am J Cardiol 98 4A 2006 71i 76i
49. K.C. Maki, J.M. McKenney, and M.S. Reeves Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia Am J Cardiol 102 2008 429 433
50. C.M. Ballantyne, H.E. Bays, and J.J. Kastelein AMR101 lowers triglycerides, atherogenic lipoprotein, phospholipase A2, and high-sensitivity C-reactive protein levels in patients with high triglycerides and on background statin therapy (the ANCHOR study) Circulation 124 2011 A15071
51. TRICOR 48 mg and 145 mg (fenofibrate tablets). Prescribing information October 2010 Abbott Laboratories North Chicago, IL
52. ®(fenofibric acid delayed release capsules). Prescribing Information September 2010 Abbott Laboratories North Chicago, IL
53. ® (fenofibrate) Capsules. Prescribing information November 2009 Lupin Pharma Baltimore, MD
54. M. Elisaf Effects of fibrates on serum metabolic parameters Curr Med Res Opin 18 2002 269 276
55. R.H. Knopp, W.V. Brown, and C.A. Dujovne Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia Am J Med 83 1987 50 59
56. G.M. Keating Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus Am J Cardiovasc Drugs 11 2011 227 247
57. Niaspan® Tablets (niacin extended release tablets). Prescribing information December 2010 Abbott Laboratories North Chicago IL
58. J.M. Morgan, D.M. Capuzzi, and J.R. Guyton Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial J Cardiovasc Pharmacol Ther 1 1996 195 202
59. D.M. Capuzzi, J.R. Guyton, and J.M. Morgan Efficacy and safety of an extended-release niacin (Niaspan): a long-term study Am J Cardiol 82 12A 1998 74U 81U
60. J. McKenney New perspectives on the use of niacin in the treatment of lipid disorders Arch Intern Med 164 2004 697 705
61. L.A. Carlson Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review J Intern Med 258 2005 94 114
62. R.H. Bakker-Arkema, M.H. Davidson, and R.J. Goldstein Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia JAMA 275 1996 128 133
63. D.B. Hunninghake, E.A. Stein, and H.E. Bays Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia Coron Artery Dis 15 2004 115 123
64. W.S. Harris, H.N. Ginsberg, and N. Arunakul Safety and efficacy of Omacor in severe hypertriglyceridemia J Cardiovasc Risk 4 1997 385 391
65. E. Balk Effects of Omega-3-Fatty Acids on Cardiovascular Risk Factors and Intermediate Markers of Cardiovascular Disease 2004 Agency for Healthcare Research and Quality Rockville, MD
66. K.C. Maki, M.R. Dicklin, A.L. Lawless, and M.S. Reeves Omega-3 fatty acids for the treatment of elevated triglycerides Clin Lipidol 4 2009 425 437
67. H.E. Bays, C.M. Ballantyne, and J.J. Kastelein Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels [from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with open-label Extension (MARINE) trial] Am J Cardiol 108 2011 682 690
68. ® (omega-3-acid ethyl esters capsules). Prescribing Information December 2010 Glaxo SmithKline Research Triangle Park, NC
69. C.J. Packard Overview of fenofibrate Eur Heart J 19 Suppl A 1998 A62 A65
70. A.C. Goldberg, G. Schonfeld, and E.B. Feldman Fenofibrate for the treatment of type IV and V hyperlipoproteinemias: a double-blind, placebo-controlled multicenter US study Clin Ther 11 1989 69 83
71. C.M. Ballantyne, H. Bertolami, and H.R. Hernandez Garcia Achieving LDL cholesterol, non-HDL cholesterol and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapy (MERCURY) II Am Heart J 151 2006 975.e1 975.e9
72. J. Shepherd, S.M. Cobbe, and I. Ford Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group N Engl J Med 333 1995 1301 1307
73. F.M. Sacks, M.A. Pfeffer, and L.A. Moye The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators N Engl J Med 335 1996 1001 1009
74. F.M. Sacks, A.M. Tonkin, and J. Shepherd Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project Circulation 102 2000 1893 1900
75. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
76. C.M. Ballantyne, A.G. Olsson, and T.J. Cook Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S Circulation 104 2001 3046 3051
77. P.M. Ridker, E. Danielson, F.A. Fonseca JUPITER Study Group Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
78. R.J. Glynn, W. Koenig, and B.G. Nordestgaard Rosuvastatin for primary prevention in older individuals with high C-reactive protein and low LDL levels: exploratory analysis of a randomized trial Ann Intern Med 152 2010 488 496
79. Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
80. J.R. Downs, M. Clearfield, and S. Weis Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 1998 1615 1622
81. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1998 1349 1357
82. T.R. Pedersen, A.G. Olsson, O. Faergeman for the Scandinavian Simvastatin Survival Study Group Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) Circulation 97 1998 1453 1460
83. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,535 high-risk individuals: a randomized placebo-controlled trial Lancet 360 2002 7 22
84. P.S. Sever, B. Dahlöf, N.R. Poulter ASCOT Investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 2003 1149 1158
85. E.J. Topol Intensive statin therapy - a sea change in cardiovascular prevention N Engl J Med 305 2004 1562 1564
86. F.R. Pedersen, O. Faergeman, J.J. Kastelein Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA 294 2005 2437 2445
87. J. Shepherd, P. Barter, and R. Carmena Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study Diabetes Care 29 2006 1220 1226
88. M. Miller, C.P. Cannon, S.A. Murphy for the PROVE IT-TIMI 22 Investigators Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 Trial J Am Coll Cardiol 51 2008 724 730
89. M.H. Frick, O. Elo, and K. Haapa Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease N Engl J Med 317 1987 1237 1245
90. V. Manninen, L. Tenkanen, and P. Koskinen Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment Circulation 85 1992 37 45
91. L. Tenkanen, M. Manttari, and P.T. Kovanen Gemfibrozil in the treatment of dyslipidemia: An 18-year mortality follow-up of the Helsinki Heart Study Arch Intern Med 166 2006 743 748
92. The BIP Study Group Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study Circulation 102 2000 21 27
93. H.B. Rubins, S.J. Robins, D. Collins for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol N Engl J Med 341 1999 410 418
94. A. Keech, R.J. Simes, P. Barter FIELD study investigators Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 2005 1849 1861
95. R. Scott, R. O'Brien, G. Fulcher Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study Diabetes Care 32 2009 493 498
96. H.N. Ginsberg, M.B. Elam, L.C. Lovato ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1564
97. M. Yokoyama, H. Origasa, M. Matsuzaki Japan EPA lipid intervention study (JELIS) Investigators Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis Lancet 369 2007 1090 1098
98. Y. Saito, M. Yokoyama, H. Origasa for the JELIS Investigators, Japan Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS) Atherosclerosis 200 2008 135 140
99. W.E. Boden, J.L. Probstfield, T. Anderson AIM-HIGH Investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
100. H.E. Bays, E.M. Roth, and J.M. McKenney The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia Diabetes Care 33 2010 2113 2116
101. D. Preiss, S.R. Seshasai, and P. Welsh Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis JAMA 305 2011 2556 2564
102. N. Sattar, D. Preiss, and H.M. Murray Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 2010 735 742
103. A.L. Culver, I.S. Ockene, and R. Balasubramanian Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative Arch Intern Med 172 2012 144 152
104. K. Musa-Veloso, M.A. Binns, and A.C. Kocenas Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid dose-dependently reduce fasting serum triglycerides Nutr Rev 68 2010 155 167
105. K.C. Maki, and T.M. Rains Low-dose eicosapentaenoic acid and/or docosahexaenoic acid and triglyceride lowering Nutr Rev 68 2010 567 568
106. P.M. Kris-Etherton, W.S. Harris, L.J. Appel for the American Heart Association Nutrition Committee Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease Circulation 106 2002 2747 2757
107. H.E. Bays Fish oils in the treatment of dyslipidemia and cardiovascular disease P.O. Kwiterovich Jr. The John Hopkins Textbook of Dyslipidemia 2010 Lippincott Williams & Wilkins Philadelphia 245 257
108. A.C. Skulas-Ray, P.M. Kris-Etherton, and W.S. Harris Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia Am J Clin Nutr 93 2011 243 252
109. G. De Backer, E. Ambrosioni, and K. Borch-Johnsen European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. Third Joint Task Force of European and Other Societies on Cardiovascular Prevention in Clinical Practice Eur Heart J 24 2003 1601 1610
110. C. Von Schacky, and W.S. Harris Cardiovascular benefits of omega-3 fatty acids Cardiovasc Res 73 2007 310 315
111. D.C. Chan, G.F. Watts, and P.H.R. Barrett Regulatory effects of HMG CoA reductase inhibitors and fish oils on Apo B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia Diabetes 51 2002 2377 2386
112. D.C. Chan, G.F. Watts, and T.A. Mori Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity Am J Clin Nutr 77 2003 300 307
113. H.E. Bays, A.P. Tighe, and R. Sadovsky Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications Expert Rev Cardiovasc Ther 6 2008 391 409
114. W.S. Harris, M. Miller, A.P. Tighe, M.H. Davidson, and E.J. Schaefer Omega-3 fatty acids and coronary heart disease risk: Clinical and mechanistic perspectives Atherosclerosis 187 2008 12 24
115. 2 mass in men and women with mixed dyslipidemia J Clin Lipidol 5 2011 483 492
116. W.S. Harris n-3 fatty acids and serum lipoproteins: human studies Am J Clin Nutr 65 Suppl 5 1997 1645S 1654S
117. H.J. Pownall, D. Brauchi, and C. Kilinc Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins Atherosclerosis 143 1999 285 297
118. L. Calabresi, D. Donati, and F. Pazzucconi Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses Atherosclerosis 148 2000 387 396
119. M.H. Davidson, E.A. Stein, and H.E. Bays Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 4 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study Clin Ther 29 2007 1354 1367
120. K.C. Maki, M.R. Dicklin, M.H. Davidson COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to simvastatin therapy Am J Cardiol 105 2010 1409 1412
121. M.L. Burr, A.M. Fehily, and J.F. Gilbert Effects of changes in fat, fish and fibre intakes on death and myocardial infarction: Diet And Reinfarction Trial (DART) Lancet 2 1989 757 761
122. GISSI-Prevenzione Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial: Gruppo Italiano per lo Studio della Sopravvivenza nell' infarto miocardico Lancet 354 1999 447 455
123. M. Matsuzaki, M. Yokoyama, Y. Saito for the JELIS Investigators, Japan Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease: secondary prevention analysis from JELIS Circ J 73 2009 1283 1290
124. T.A. Jacobson, S.B. Glickstein, and J.D. Rowe Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review J Clin Lipidol 6 2012 5 18
125. H. Bays, J. McElhattan, B.S. Bryzinski Gallant 6 Study Group A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus Diab Vasc Dis Res 4 2007 181 193
126. S.J. Robins, D. Collins, J.T. Wittes VA-HIT Study Group, Veterans Affairs High-Density Lipoprotein Intervention Trial Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial JAMA 285 2001 1585 1591
127. L. Tenkanen, M. Manttari, and V. Manninen Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study Circulation 92 1995 1779 1785
128. F.M. Sacks, V.J. Carey, and J.C. Fruchart Combination lipid therapy in type 2 diabetes N Engl J Med 363 2010 692 695
129. V.S. Kamanna, and M.L. Kashap Mechanism of action of niacin Am J Cardiol 101 2008 20B 26B
130. M.B. Elam, D.B. Hunninghake, and K.B. Davis Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study, a randomized trial. Arterial Disease Multiple Intervention Trial JAMA 284 2000 1263 1270
131. J. Shepherd, J. Betteridge, and L. Van Gaal Nicotinic acid in the management of dyslipidemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel Curr Med Res Opin 21 2005 665 682
132. K. Cheng, T.J. Wu, and K.K. Wu Antagonism of the prostaglandin D2 receptor I suppresses nicotinic acid-induced vasodilation in mice and humans Proc Natl Acad Sci U S A 103 2006 6682 6687
133. H.E. Bays, and C. Ballantyne What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush? Curr Opin Lipidol 20 2009 467 476
134. P.L. Canner, K.G. Berge, and N.K. Wenger Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin J Am Coll Cardiol 8 1986 1245 1255
135. G. Brown, J.J. Albers, and L.D. Fisher Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B N Engl J Med 323 1990 1289 1298
136. X.Q. Zhao, J.S. Morse, and A.A. Dowdy Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study) Am J Cardiol 93 2004 307 312
137. T.C. Villines, E.J. Stanek, and P.J. Devine The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol-6 HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration J Am Coll Cardiol 55 2010 2721 2726
138. A.R. Vasudevan, and P.H. Jones Effective use of combination lipid therapy Curr Atheroscler Rep 8 2006 76 84
139. J.M. McKenney, P.H. Jones, and H.E. Bays Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study) Atherosclerosis 192 2007 432 437
140. P. Barter, and H.N. Ginsberg Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia Am J Cardiol 102 2008 1040 1045
141. E. Moutzouri, A. Kei, M.S. Elisaf, and H.J. Milionis Management of dyslipidemias with fibrates, alone or in combination with statins: role of delayed-release fenofibric acid Vasc Health Risk Manag 6 2010 525 539
142. M.J. Chapman, H.N. Ginsberg, P. Amarenco European Atherosclerosis Society Consensus Panel Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management Eur Heart J 32 2011 1345 1361
143. J.M. McKenney, M. Farnier, and K.W. Lo Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia J Am Coll Cardiol 47 2006 1584 1587
144. E.M. Roth, H.E. Bays, and A.D. Forker Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects J Cardiovasc Pharmacol 54 2009 196 203
145. H.E. Bays Statin safety: an overview and assessment of the data - 2005 Am J Cardiol 97 8A 2006 S6 S26